Homepage Top Section1

The SOLO-3 late-stage trial, which evaluated the efficacy and safety of Lynparza, featured 266 patients whose ovarian cancer relapsed following two or more lines of treatment. Patients were

UPSA is a French pharmaceutical manufacturer, which develops and produces pharmaceutical drugs and supplements for everyday ailments. The company provides various products in therapeutic areas, including pain, cough

VE303 is claimed to be the first drug featuring a rationally-defined bacterial consortium to advance to phase 2 study. The earlier announced phase 1a/1b study showed rapid, durable,

The deal will allow AMAG to acquire global rights of ciraparantag, a next generation anticoagulant reversal agent, from Perosphere. As per terms of the deal, Perosphere equityholders will

Circassia has issued a notice of option exercise to AstraZeneca related to US commercial rights of Tudorza. The company intends to complete the option exercise by the end

Zolgensma was previously granted breakthrough therapy designation by the US regulator. Novartis expects a regulatory action to be taken on the gene replacement therapy in May 2019. According

Gilenya is claimed to be the first and only oral disease-modifying treatment approved for children and adolescents in the Europe. The approval allows the company to market Gilenya

Developed by AstraZeneca with MedImmune, its research and development arm, Fasenra was in-licensed from BioWa, a subsidiary of Japanese pharma company Kyowa Hakko Kirin. Considered to be a

The European approval for Luxturna is for the treatment of inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations in both adult and pediatric patients who have sufficient